August 2, 2012
Citing the "emergence of a serious safety issue," Bristol-Myers Squibb Co. said Wednesday it was voluntarily suspending the Phase II study of a hepatitis C drug candidate, BMS-986094. Earlier this year, BMS paid $2.5 billion to acquire Inhibitex Inc., the company that developed the nucleotide polymerase inhibitor formerly known as INX-189. "The cause of the safety issue and any potential relationship to the study drug are unknown at this time," BMS said in a statement. The company currently is assessing all the study patients and will decide on next steps following an evaluation of patient data.
Wall Street Journal
08.02.2012; Saabira Chaudhuri
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART|
|Final HIV Research Highlights From CROI 2017|
|With Possibilities for Long-Acting HIV Treatment, Modern Science Creates Modern ART|
|Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study|
|No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study|
|Really Rapid Review -- CROI 2017, Seattle|